In 2013, Bryan Johnson sold Venmo to PayPal for $800 million.
In 2015, Bryan Johnson invested into the Series A Round of Ginkgo Bioworks at a valuation of less than $100 million. Last month, Ginkgo Bioworks went public and currently has a valuation of $28 billion.
In 2016, Bryan Johnson founded Kernel which has developed revolutionary helmet-like devices that can see and record brain activity.
Today, Cybin (CYBN) received FDA Investigational New Drug Authorization to proceed with CYBN's sponsored feasibility study using Kernel’s Flow technology to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics.
Past performance is not an indicator of future returns. NIA is not an investment advisor and does not /a investment advice. Always do your own research and make your own investment decisions. This message is not a solicitation or recommendation to buy, sell, or hold securities. NIA has received compensation from CYBN of USD$100,000 cash for a one-year marketing contract. This message is meant for informational and educational purposes only and does not provide investment advice.